• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[无酸无溃疡:如此简单的公理?]

[No acid, no ulcer: such a simple axiom?].

作者信息

Dobrilla G, Amplatz S, Benvenuti S, Di Fede F, Thaler W

机构信息

Divisione di Gastroenterologia, Ospedale Generale Regionale, Bolzano, Italia.

出版信息

An Med Interna. 1991 Sep;8(9):461-5.

PMID:1958784
Abstract

According to the traditional view gastric acid and pepsin are a sine qua non for ulcer development. Acid suppression, however, is far from being the only successful therapeutic approach, and similar healing rates are achieved by drugs with substantially different mechanisms of action--antacids, H2-antagonists, antimuscarinics, cytoprotective and site-protective agents--thus denoting a multifactorial pathogenesis. Even with the antisecretory compounds, the relationship between gastric acid and ulcer healing gives rise to perplexity: antacids prove effective at widely varying doses; pirenzipine and H2-blockers, which are clinically equieffective, differ considerably in antisecretory efficacy; H2-antagonist studies on early vs late postprandial dosing yield contradictory clinical results; morning and bedtime single administrations of H2-antagonists prove equiactive on ulcer healing, leading to a reappraisal of the alleged importance of nocturnal acidity. Ulcer sealants such as colloidal bismuth and sucralfate prove as effective as H2-antagonists despite their total lack of antisecretory activity, thereby apparently undermining the primary pathogenetic role of acid. However, with the spectacular 100% healing rates achieved by the protonpump blocker, omeprazole, the wheel has come full circle, and gastric acid appears to re-emerge as a primary element in pathogenesis. Specific therapy, based on the predominant pathogenetic factor involved, is likely to be a feasible proposition, but, at present, remains little more than a remote possibility.

摘要

按照传统观点,胃酸和胃蛋白酶是溃疡形成的必要条件。然而,抑制胃酸远非唯一成功的治疗方法,作用机制截然不同的药物——抗酸剂、H2拮抗剂、抗毒蕈碱药、细胞保护剂和局部保护剂——都能达到相似的愈合率,这表明发病机制是多因素的。即使是抗分泌化合物,胃酸与溃疡愈合之间的关系也令人困惑:抗酸剂在广泛不同的剂量下都证明有效;临床效果相当的哌仑西平和H2阻滞剂,其抗分泌功效却有很大差异;关于H2拮抗剂餐后早期与晚期给药的研究得出相互矛盾的临床结果;H2拮抗剂早晨和睡前单次给药对溃疡愈合的效果相同,这导致人们重新审视所谓夜间胃酸的重要性。尽管胶体铋和硫糖铝等溃疡封闭剂完全没有抗分泌活性,但它们与H2拮抗剂一样有效,这显然削弱了胃酸在发病机制中的主要致病作用。然而,随着质子泵阻滞剂奥美拉唑取得惊人的100%愈合率,情况又回到了原点,胃酸似乎再次成为发病机制中的主要因素。基于主要致病因素的特异性治疗可能是一个可行的方案,但目前,这仍然只是一个遥远的可能性。

相似文献

1
[No acid, no ulcer: such a simple axiom?].[无酸无溃疡:如此简单的公理?]
An Med Interna. 1991 Sep;8(9):461-5.
2
The gastric acid conundrum in peptic ulcer.消化性溃疡中的胃酸难题
Ital J Gastroenterol. 1990 Jun;22(3):142-6.
3
Pathogenesis and therapy of peptic ulcer disease.消化性溃疡病的发病机制与治疗
J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. doi: 10.1097/00004836-199000000-00002.
4
What are the current possibilities in treating peptic ulcer disease?目前治疗消化性溃疡疾病有哪些可行的方法?
Aliment Pharmacol Ther. 1987;1 Suppl 1:468S-492S. doi: 10.1111/j.1365-2036.1987.tb00657.x.
5
Medical treatment of peptic ulcers.消化性溃疡的医学治疗。
Surg Annu. 1985;17:219-33.
6
Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.治疗消化性溃疡的局部活性药物。重点关注枸橼酸铋钾和硫糖铝。
J Clin Gastroenterol. 1992 Apr;14(3):192-8.
7
Inhibition of gastric acid secretion and therapeutic results: is there any correlation?
Ital J Gastroenterol. 1990;22 Suppl 1:2-4.
8
Refractory peptic ulcers.难治性消化性溃疡
J Assoc Acad Minor Phys. 1992;3(3):95-102.
9
Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease.硫糖铝及其他非抗分泌药物在消化性溃疡疾病治疗中的应用
Methods Find Exp Clin Pharmacol. 1989;11 Suppl 1:113-6.
10
Acid suppression therapy: where do we go from here?抑酸治疗:我们将何去何从?
Dig Dis. 2006;24(1-2):11-46. doi: 10.1159/000091298.